Core Scientific Wins AMD's Approval, As Meltdown/Bottoming Offers A Cheap Buying Opportunity

The article characterizes Core Scientific’s AMD warrant agreement, valued at $704.1M, as strategically attractive against potential bull-case revenue opportunities of more than $66B. It also warns that the backlog may require elevated future capex, weigh on free cash flow and the balance sheet, and increase near-term volatility.

Analysis

The key asymmetry is execution, not headline revenue potential. A large deployment can validate AMD’s ability to win AI infrastructure demand and improve its position with other customers, but only if hardware ships, systems are accepted, and software performance supports repeat orders. The read-through to AMD is therefore positive but not equivalent to booked, high-margin revenue; verify delivery schedules and whether the economics are incremental to existing guidance.

For CORZ, contracted demand may reduce utilization risk while increasing exposure to construction, power availability, equipment timing, and funding costs. If spending precedes customer payments or capacity ramp, the market may discount the backlog rather than capitalize it—especially if leverage, dilution, or free-cash-flow pressure worsens. The stated revenue ceiling is a bull case, not a valuation input without term, timing, and margin detail.

Over days, sentiment and positioning may dominate. Over 1–3 months, contract disclosures, capex guidance, financing terms, and deployment milestones should determine whether the market treats this as de-risked demand or a capital-intensive commitment. Over 6–18 months, successful delivery could strengthen AMD’s competitive credibility; delays or weak returns would expose CORZ’s balance-sheet sensitivity. The warrant’s direction, exercise/vesting terms, and dilution implications are unclear and should be verified before assigning value. Main falsifiers: CORZ raises capex or financing needs materially, misses build milestones, or AMD’s guidance fails to reflect incremental shipments.

Key Decisions for Investors

• Do not underwrite CORZ from the headline revenue ceiling. Before adding exposure, verify contract duration, minimum purchase or payment commitments, deployment milestones, power access, capex schedule, and customer concentration.
• Conditional relative-value idea: after confirming the contract is incremental to AMD guidance, consider a small long AMD / short CORZ pair to express lower balance-sheet execution risk at AMD versus CORZ’s buildout and financing risk. Keep sizing modest; reverse if CORZ demonstrates on-time delivery, contained capex, and improving cash generation, or if AMD does not show incremental demand in guidance.
• Treat the warrant as a diligence item, not automatically as cheap consideration: confirm who receives the warrants, exercise price, vesting triggers, expiry, and potential share dilution. Reassess CORZ exposure if the terms materially increase financing or dilution risk.
• Monitor CORZ quarterly capex, liquidity and free-cash-flow trajectory alongside construction and power milestones; a material deterioration or delay would strengthen the downside thesis, while funded, on-schedule capacity with customer payments would weaken it.